Pramipexole

Alias: Mirapex;Pramipexole dihydrochloride monohydrate;

Product Details:
Place of Origin: China
Certification: ISO9001
Brand:YuanCheng

Payment & Shipping Terms:

Minimum Order Quantity:1kg
Supply Ability:500kg/month
Delivery Time:within 24 hours after payment
Payment Terms:Western Union, MoneyGram, T/T
Package:25KG/NET Fiber Drum
Appearance:white to slight yellow powder

Product Description:

CAS: 191217-81-9
M.F.: C10H21Cl2N3OS
M.W. : 302.26
Purity:99%

M.S.:


Pramipexole has some of the same effects as a chemical called dopamine, which occurs naturally in your body. Low levels of dopamine in the brain are associated with Parkinson's disease. Pramipexole is used to treat symptoms of Parkinson's disease, such as stiffness, tremors, muscle spasms, and poor muscle..

While pramipexole is used clinically .its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to interrogate the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders.[6] Of note, it appears that pramipexole, in addition to having effects on dopamine D3 receptors, may also affect mitochondrial function via a mechanism that remains less understood. A pharmacological approach to separate dopaminergic from non-dopaminergic (e.g. mitochondrial) effects of pramipexole has been to study the effects of the R-stereoisomer of pramipexole (which has much lower affinity to the dopamine receptors when compared to the S-isomer) side-by-side with the effects of the S-isomer.

Usage:
Pramipexole (Mirapex, Mirapexin, Sifrol) is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole is also sometimes used off-label as a treatment for cluster headache and to counteract problems with sexual dysfunction experienced by some users of selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder.It is also being investigated for the treatment of clinical depression and fibromyalgia.

Permanent link: http://www.vvchem.com/sell/cas:191217-81-9,3323139.html